Evaluating process utilities for the treatment burden of chemotherapy in multiple myeloma in Japan: a time trade-off valuation study

References

• Japanese Society of Hematology. Clinical practice guidelines for hematopoietic malignancies [Internet]. [updated 2018; cited 2022 Aug 30]. Available from: http://www.jshem.or.jp/gui-hemali/index.html
   Google Scholar
• Handa H. Multiple myeloma: from diagnosis to the up-to-date treatment. Topics: I. Epidemiology and prognostic change of multiple myeloma. J Jpn Soc Intern Med. 2016;105(7):1202–1208.
   PubMedGoogle Scholar
• Center for Cancer Control and Information Services. Cancer statistics in Japan [Internet]; 2021 [cited 2022 Aug 30]. Available from: https://ganjoho.jp/public/qa_links/report/statistics/2021_en.html
   Google Scholar
• Munshi NC, Anderson LD Jr., Shah N, et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results. J Clin Oncol. 2020;38(15_suppl):8503–8503.
   Web of Science ®Google Scholar
• Munshi NC, Anderson LD Jr., Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371–1376.
   PubMed Web of Science ®Google Scholar
• Matza LS, Stewart KD, Lloyd AJ, et al. Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health. 2021;24(6):812–821.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE health technology evaluations: the manual [Internet]. [cited 2023 Feb 23]. Available from: https://www.nice.org.uk/process/pmg36/resources/nice-health-technology-evaluations-the-manual-pdf-72286779244741
   Google Scholar
• Higgins A, Barnett J, Meads C, et al. Does convenience matter in health care delivery? A systematic review of convenience-based aspects of process utility. Value Health. 2014;17(8):877–887.
   PubMed Web of Science ®Google Scholar
• Higginson IJ, Sen-Gupta GJ. Place of care in advanced cancer: a qualitative systematic literature review of patient preferences. J Palliat Med. 2000;3(3):287–300.
   PubMedGoogle Scholar
• Hall F, de Freitas HM, Kerr C, et al. Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. Qual Life Res. 2019;28(5):1191–1199.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Piglowska N, Ciulla T, et al. Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. Br J Ophthalmol. 2019;103(11):1610–1614.
   PubMed Web of Science ®Google Scholar
• Matza LS, Deger KA, Vo P, et al. Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. Qual Life Res. 2019;28(9):2359–2372.
   PubMed Web of Science ®Google Scholar
• Devlin NJ, Tsuchiya A, Buckingham K, et al. A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach. Health Econ. 2011;20(3):348–361.
   PubMed Web of Science ®Google Scholar
• Mulhern B, Rowen D, Jacoby A, et al. The development of a QALY measure for epilepsy: NEWQOL-6D. Epilepsy Behav. 2012;24(1):36–43.
   PubMed Web of Science ®Google Scholar
• Rowen D, Mulhern B, Banerjee S, et al. Estimating preference-based single index measures for dementia using DEMQOL and DEMQOL-Proxy. Value Health. 2012;15(2):346–356.
   PubMed Web of Science ®Google Scholar
• Mukuria C, Rowen D, Brazier JE, et al. Deriving a preference-based measure for myelofibrosis from the EORTC QLQ-C30 and the MF-SAF. Value Health. 2015;18(6):846–855.
   PubMed Web of Science ®Google Scholar
• Statistics Bureau of Japan. Final report of 2015 “population and households of Japan” [Internet]. [cited 2022 Aug 30]. Available from: https://www.stat.go.jp/english/data/kokusei/2015/final_en/final_en.html
   Google Scholar
• Statistics Bureau of Japan. Employment Status Survey in 2017 [Internet]. [cited 2022 Aug 30]. Available from: https://www.stat.go.jp/english/data/shugyou/pdf/sum2017.pdf
   Google Scholar
• Household Statistics Office. Summary report of comprehensive survey of living conditions [Internet]; 2019 [cited 2022 Aug 30]. Available from: https://www.mhlw.go.jp/english/database/db-hss/dl/report_gaikyo_2019.pdf
   Google Scholar
• Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24(8):1193–1202.
   PubMed Web of Science ®Google Scholar
• Hatswell AJ, Burns D, Baio G, et al. Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data. Health Econ. 2019;28(5):653–665.
   PubMed Web of Science ®Google Scholar
• Aristides M, Barlev A, Barber B, et al. Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom. Health Qual Life Outcomes. 2015;13:181.
   PubMed Web of Science ®Google Scholar
• Guest JF, Naik N, Sladkevicius E, et al. Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leuk Lymphoma. 2012;53(5):928–933.
   PubMed Web of Science ®Google Scholar
• Howell TA, Matza LS, Jun MP, et al. Health state utilities for adverse events associated with chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Pharmacoecon Open. 2022;6(3):367–376.
   PubMed Web of Science ®Google Scholar
• Johnson ES, Sullivan SD, Mozaffari E, et al. A utility assessment of oral and intravenous ganciclovir for the maintenance treatment of AIDS-related cytomegalovirus retinitis. Pharmacoeconomics. 1996;10(6):623–629.
   PubMed Web of Science ®Google Scholar
• Osborne RH, De Abreu Lourenço R, Dalton A, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health. 2007;10(6):451–456.
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219–230.
   PubMed Web of Science ®Google Scholar
• Chancellor J, Aballéa S, Lawrence A, et al. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics. 2008;26(3):217–234.
   PubMed Web of Science ®Google Scholar